抗人 SLAMF7 抗体对
01AB01586
SLAM family member 7 (SLAMF7), also known as CD319, is a self-ligand receptor protein primarily expressed on immune cells, including natural killer (NK) cells and B cells. It plays an important role in immune cell activation, signaling, and regulation. SLAMF7 activates pathways such as Src kinase and phospholipase C-gamma (PLC-γ) in NK cells, promoting cytolytic activity and secretion of cytokines like lymphotoxin A and TNF-α in B cells, which support proliferation and immune responses. SLAMF7 is located on chromosome 1 and the protein is involved in processes like T cell activation and natural killer cell regulation. Clinically, SLAMF7 is a key marker for plasma cells and malignant plasma cells in multiple myeloma (MM), distinguishing it from traditional markers by being more stable. It is also the target of the therapeutic antibody elotuzumab used in MM treatment.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- SLAMF7
- 基因别名
- CS1
- 蛋白别名
- SLAM family member 7; SLAMF7
- UniProt
- Q9NQ25
- 物种
- Human
产品详情
- 靶点名称
- SLAMF7
- 蛋白名称
- SLAM family member 7
- 蛋白别名
- SLAM family member 7; CD2 subset 1; CD2-like receptor-activating cytotoxic cells; CRACC; Membrane protein FOAP-12; Novel Ly9; Protein 19A; CD antigen CD319
- 靶点基因名
- SLAMF7
- 基因别名
- CS1
- UniProt
- Q9NQ25
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
SLAM family member 7 (SLAMF7), also known as CD319, is a self-ligand receptor protein primarily expressed on immune cells, including natural killer (NK) cells and B cells. It plays an important role in immune cell activation, signaling, and regulation. SLAMF7 activates pathways such as Src kinase and phospholipase C-gamma (PLC-γ) in NK cells, promoting cytolytic activity and secretion of cytokines like lymphotoxin A and TNF-α in B cells, which support proliferation and immune responses. SLAMF7 is located on chromosome 1 and the protein is involved in processes like T cell activation and natural killer cell regulation. Clinically, SLAMF7 is a key marker for plasma cells and malignant plasma cells in multiple myeloma (MM), distinguishing it from traditional markers by being more stable. It is also the target of the therapeutic antibody elotuzumab used in MM treatment.